Switch theme
Sign up to access all valuation multiples
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
1997
355
LTM Revenue $216M
LTM EBITDA -$8.7M
$3.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zealand Pharma has a last 12-month revenue of $216M and a last 12-month EBITDA of -$8.7M.
In the most recent fiscal year, Zealand Pharma achieved revenue of $9.0M and an EBITDA of -$147M.
Zealand Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zealand Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $49.4M | $9.0M | XXX | XXX | XXX |
| Gross Profit | $15.0M | $46.6M | XXX | XXX | XXX |
| Gross Margin | 30% | 516% | XXX | XXX | XXX |
| EBITDA | -$94.9M | -$147M | XXX | XXX | XXX |
| EBITDA Margin | -192% | -1633% | XXX | XXX | XXX |
| Net Profit | -$173M | -$101M | XXX | XXX | XXX |
| Net Margin | -351% | -1123% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Zealand Pharma's stock price is DKK 452 (or $65).
Zealand Pharma has current market cap of DKK 31.9B (or $4.6B), and EV of DKK 24.1B (or $3.5B).
See Zealand Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.5B | $4.6B | XXX | XXX | XXX | XXX | $-0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Zealand Pharma has market cap of $4.6B and EV of $3.5B.
Zealand Pharma's trades at 16.1x LTM EV/Revenue multiple, and -397.7x LTM EBITDA.
Analysts estimate Zealand Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Zealand Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.5B | XXX | XXX | XXX |
| EV/Revenue | 384.4x | XXX | XXX | XXX |
| EV/EBITDA | -23.5x | XXX | XXX | XXX |
| P/E | -29.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -25.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpZealand Pharma's NTM/LTM revenue growth is 186%
Zealand Pharma's revenue per employee for the last fiscal year averaged $25K, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Zealand Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Zealand Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Zealand Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -82% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1633% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 55% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -1447% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $25K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 110% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 256% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1467% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2112% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zealand Pharma acquired XXX companies to date.
Last acquisition by Zealand Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Zealand Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Zealand Pharma founded? | Zealand Pharma was founded in 1997. |
| Where is Zealand Pharma headquartered? | Zealand Pharma is headquartered in Denmark. |
| How many employees does Zealand Pharma have? | As of today, Zealand Pharma has 355 employees. |
| Who is the CEO of Zealand Pharma? | Zealand Pharma's CEO is Mr. Adam Steensberg. |
| Is Zealand Pharma publicy listed? | Yes, Zealand Pharma is a public company listed on CSE. |
| What is the stock symbol of Zealand Pharma? | Zealand Pharma trades under ZEAL ticker. |
| When did Zealand Pharma go public? | Zealand Pharma went public in 2010. |
| Who are competitors of Zealand Pharma? | Similar companies to Zealand Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zealand Pharma? | Zealand Pharma's current market cap is $4.6B |
| What is the current revenue of Zealand Pharma? | Zealand Pharma's last 12-month revenue is $216M. |
| What is the current EBITDA of Zealand Pharma? | Zealand Pharma's last 12-month EBITDA is -$8.7M. |
| What is the current EV/Revenue multiple of Zealand Pharma? | Current revenue multiple of Zealand Pharma is 16.1x. |
| What is the current EV/EBITDA multiple of Zealand Pharma? | Current EBITDA multiple of Zealand Pharma is -397.7x. |
| What is the current revenue growth of Zealand Pharma? | Zealand Pharma revenue growth between 2023 and 2024 was -82%. |
| Is Zealand Pharma profitable? | Yes, Zealand Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
